Drug Type Small molecule drug, Monoclonal antibody |
Synonyms AR-160 |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC47H51NO14 |
InChIKeyRCINICONZNJXQF-MZXODVADSA-N |
CAS Registry33069-62-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 1 | - | - |